Status:
UNKNOWN
A Retrospective Study on Multiple Classifier Endometrial Cancer
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions:
Uterine Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Endometrial cancer is not a single entity but rather a very heterogeneous group of diseases. Historically, endometrial cancer patients have been classified as endometrioid (type I) or non-endometrioid...
Eligibility Criteria
Inclusion
- Inclusion criteria were the following: (i) histological diagnosis of endometrial cancer; (ii) execution of hysterectomy (with or without salpingo-oophorectomy) with or without nodal dissection; (iii) apparent early-stage disease; (iv) conventional pathological evaluation; and (v) molecular/genomic evaluation of the disease (including at least POLE sequencing, MMR protein immunostaining or MSI assessment, p53 immunostaining or TP53 sequencing). Exclusion criteria were: (i) consent withdrawal, (ii) execution of neoadjuvant therapy, and (iii) stage IV disease.
Exclusion
Key Trial Info
Start Date :
July 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05976113
Start Date
July 27 2023
End Date
August 31 2023
Last Update
August 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, Italy, 20133